Zika Virus Immune Globulin (ZIKV-IG)
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Zika Virus Infection
Conditions
Zika Virus Infection, Zika Virus Disease
Trial Timeline
Jun 27, 2018 → Mar 6, 2019
NCT ID
NCT03624946About Zika Virus Immune Globulin (ZIKV-IG)
Zika Virus Immune Globulin (ZIKV-IG) is a phase 1 stage product being developed by Emergent BioSolutions for Zika Virus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03624946. Target conditions include Zika Virus Infection, Zika Virus Disease.
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03624946 | Phase 1 | Completed |
Competing Products
5 competing products in Zika Virus Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1893 | Moderna | Phase 1 | 0 |
| mRNA-1325 | Moderna | Phase 1 | 0 |
| mRNA-1893 | Moderna | Phase 2 | 0 |
| VLA1601 + Placebo | Valneva SE | Phase 1 | 23 |
| VLA1601 + CpG 1018® + 3M-052-AF | Valneva SE | Phase 1 | 23 |